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786In vivo electroporation of constitutively expressed
HIF-1a plasmid DNA improves neovascularization
in a mouse model of limb ischemia
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Robert L. Wilensky, MD,d and Emile R. Mohler III, MD,a Philadelphia, Pa
Objective: Hypoxia-inducible factor-1 alpha (HIF-1a) is a transcription factor that stimulates angiogenesis during tissue
ischemia. In vivo electroporation (EP) enhances tissue DNA transfection. We hypothesized that in vivo EP of plasmid DNA
encodingaconstitutivelyexpressedHIF-1ageneenhancesneovascularizationcomparedwith intramuscular (IM) injectionalone.
Methods: Left femoral artery ligation was performed in mice assigned to three groups: (1) HIF-EP (n[ 13); (2) HIF-IM
(n [ 14); and (3) empty plasmid (pVAX)-EP (n [ 12). A single dose of HIF-1a or pVAX DNA (20 mL of 5 mg/mL
each) was injected into the ischemic adductor muscle followed by EP (groups one and three). Mice in group two received
IM injection of HIF-1a plasmid DNA alone. From preligation to days 0, 3, 7, 14, and 21 postligation, limb perfusion
recovery quantiﬁed by laser Doppler perfusion imager, limb function, and limb necrosis were measured. On day 21, the
surviving mice (4-5 per group) were sacriﬁced and adductor muscle tissues stained for necrosis using hematoxylin and
eosin, capillary density (anti-CD31 antibodies), and collateral vessels via anti-a-smooth muscle actin antibodies.
Results: In vivo EP ofHIF-1aDNA signiﬁcantly improved limb perfusion (HIF-EP: 1.036 0.15 vs HIF-IM: 0.786 0.064;
P < .05, vs pVAX-EP: 0.41 6 0.019; P < .001), limb functional recovery (HIF-EP: 3.5 6 0.58 vs HIF-IM, 2.4 6 1.14; P <
.05, vs pVAX-EP: 2.4 6 1.14; P < .001), and limb autoamputation on day 21 (HIF-EP: 77% 6 12% vs HIF-IM: 43% 6
14%; P < .05 vs pVAX-EP: 17% 6 11%; P < .01). Adductor muscle tissue necrosis decreased (HIF-EP: 20.7% 6 1.75% vs
HIF-IM: 44% 6 3.73; P < .001, vs pVAX-EP: 60.05% 6 2.17%; P < .0001), capillary density increased (HIF-EP: 96.83 6
5.72 vessels/high-powered ﬁeld [hpf] vs HIF-IM: 62.87 6 2.0 vessels/hpf; P < .001, vs pVAX-EP: 39.37 6 2.76 vessels/
hpf; P < .0001), collateral vessel formation increased (HI-EP: 76.33 6 1.94 vessels/hpf vs HIF-IM: 37.5 6 1.56 vessels/
hpf; P < .0001, vs pVAX-EP: 18.5 6 1.34 vessels/hpf; P < .00001), and the vessels were larger (HIF-EP: 15,521.67 6
1298.16 mm2 vs HIF-IM: 7788.87 6 392.04 mm2; P < .001 vs pVAX-EP: 4640.25 6 614.01 mm2; P < .0001).
Conclusions: In vivo EP-mediated delivery of HIF-1a plasmid DNA improves neovascularization in a mouse model of
limb ischemia and is a potentially suitable nonviral, noninvasive intervention to facilitate therapeutic angiogenesis in
critical limb ischemia. (J Vasc Surg 2014;59:786-93.)
Clinical Relevance: There is an unmet therapeutic goal in the treatment of critical limb ischemia (CLI). Various clinical
trials have applied therapeutic angiogenesis to induce neovascularization in CLI by administering proangiogenic cyto-
kines, their associated genes, or cells. However, the results have shown limited efﬁcacy. One of the limiting factors in this
strategy is the lack of a targeted gene delivery method that introduces the gene encoding the cytokine of interest in
a speciﬁc vascular bed e a delivery modality that is noninvasive, nonviral-based, and is associated with few side effects.
Using a mouse model of limb ischemia, we report that in vivo electroporation of hypoxia-inducible factor-1 alpha plasmid
DNA enhances neovascularization and that this modality may be applied as a noninvasive, nonviral, and targeted gene
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Fig 1. A summary of experimental study design. EP, Electroporation; HIF-1a, hypoxia-inducible factor 1 alpha; IM,
intramuscular injection; LDPI, laser Doppler perfusion imager; pVAX, empty backbone plasmid DNA.
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Americans and is associated with a 20% to 30% risk of
cardiovascular death within 5 years.1 Critical limb ischemia
(CLI) represents the most severe stage of PAD and is
deﬁned by severely compromised arterial ﬂow and chronic
ischemic rest pain, tissue loss and nonhealing ulcers, or
gangrene. The cardiovascular morbidity and mortality asso-
ciated with CLI is even higher e up to 20% of patients will
die within the ﬁrst 12 months of diagnosis, and the 5-year
mortality rate exceeds 70%.2 Major limb amputation occurs
in up to 40% to 50% of CLI patients within the ﬁrst 12
months of diagnosis.3 With the aging population
continuing to increase, therapies for CLI will continue to
present a major economic burden.
The medical therapy for CLI focuses on risk factor
modiﬁcation to reduce cardiovascular events and limb
loss. Pharmacological therapy includes treatment of athero-
sclerosis with antiplatelet agents and lipid-lowering drugs
such as statins and decreasing blood pressure using anti-
hypertensive agents.4 Pain management and wound care
are crucial in the treatment of these patients and involve
a multidisciplinary approach.5 Surgical therapy remains
a cornerstone in treating these patients and involves either
open surgical procedures or intraluminal endovascular
therapies or a combination of both.6 However, a subclass
of CLI patients are not candidates for either surgical or
endovascular therapies due to either unsuitable vascular
anatomy or associated medical comorbidities.1 Such
patients have no effective treatment options except for
the management of comorbid conditions, wound care,
pain management, and eventual limb amputation.
Experiments in vascular regeneration have attempted to
use a variety of proangiogenic genes and associated growth
factors or stem cells in order to stimulate neovascularization
and perfusion in ischemic tissuee the so-called “therapeutic
angiogenesis.” Various clinical trials have shown somepromise in the use of gene- and cell-based therapies in the
treatment of CLI.However, there are barriers yet to be over-
come: (1) the intravascular delivery method is invasive, and
intramuscular (IM) injection is often suboptimal and requires
multiple administrations of the genetic or cellular agents; (2)
the right dose of genetic or cellular agent to deliver is contro-
versial; (3) there are no targeted treatment methods that
speciﬁcally deliver the gene or cell of interest to localized
vascular bed without systemic side effects; and (4) there are
host factors that neutralize the delivered genetic or cellular
materials. This experiment investigated the effectiveness of
a noninvasive gene delivery method, in vivo electroporation
(EP) of constitutively expressed hypoxia-inducible factor-1
alpha (HIF-1a) plasmid DNA, in comparison to IM injec-
tion. We hypothesized that in vivo EP-mediated delivery of
plasmid DNA encoding HIF-1a improves therapeutic efﬁ-
cacy in a mouse model of limb ischemia.METHODS
Experimental protocol. Experiments were performed
(Fig 1) to assess the following variables: (1) evaluate recovery
of limb perfusion over time using ultrasound laser Doppler;
(2) investigate the extent of limb salvage and survival from
autoamputation; and (3) assess improvement in tissue
histological features including degree of tissue necrosis.
Thirty-nine age- and gender-matched wild-type Balb/c
micewere assigned into one of the following three treatment
groups: (1) 13 mice (active treatment, HIF-1a DNA/EP);
(2) 14 mice (positive control, HIF-1a DNA/IM); and (3)
12 mice (negative control, empty plasmid [pVAX] DNA/
EP). The left limb received intervention, while the right
limb did not to allow for within-mouse comparison and
adjustment of the measured variables. At the end of day
21, an average of 4 to 5 animals per group were included
in the ﬁnal tissue analysis.
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(The Jackson Laboratory, Bar Harbor, Me), weighing 25 g
to 30 g, were cared for and operated on after approval by
the Institutional AnimalCare andUseCommittee guidelines
at the University of Pennsylvania School ofMedicine. Before
surgery, mice were anesthetized using intraperitoneal
injection of ketamine/xylazine cocktail (100 mg/kg
ketamine þ 10 mg/kg xylazine) at 0.1 mL/10 g body
weight (0.25mL to0.30mLpermouse). Femoral artery liga-
tion was performed as previously described.7,8 Brieﬂy, in
a sterile fashion, the left femoral artery was exposed, isolated
from the femoral nerve and vein, and ligated distally to the
origin of the deep femoral artery, using a 6.0 silk sutures
(Fisher Scientiﬁc, Pittsburgh, Pa). The skin was then closed
by interrupted 4.0 silk sutures (Fisher Scientiﬁc).
Plasmids. Immediately after left femoral artery liga-
tion, the adductor muscle was injected with either the
constitutively expressed HIF-1a plasmid DNA (modiﬁed
and optimized) or pVAX plasmid DNA per manufacturer’s
speciﬁcations (GenScript USA Inc, Piscataway, NJ) distal
to the ligation site using an insulin syringe with a 30-
gauge needle. Treatments were administered as follows:
(1) IM injection of 20 mL (5 mg/mL) of HIF-1a plasmid
DNA was administered in the left adductor muscle of the
experimental group (HIF-EP) followed by EP; (2) IM
injection of 20 mL (5 mg/mL) of HIF-1a plasmid DNA
was administered in the left adductor muscle of the positive
control group (HIF-IM); and (3) IM injection of 20 mL (5
mg/mL) of pVAX plasmid DNA was administered in the
left adductor muscle of the negative control group (pVAX-
EP) followed by EP.
In vivo EP. Immediately after plasmid DNA injection,
in vivo square wave-pulse EP was administered to the treat-
ment sites using the three-electrode array CELLECTRA
DNA delivery device (Inovio Biomedical, Blue Bell, Pa).
The three-electrode array consists of three 26-gauge solid
stainless steel electrodes in an isosceles triangle formation.
The speciﬁc EP conditions were set constant at a current of
0.1 amp, two pulses, 52 ms/pulse (50-100 V), and 4
seconds between pulses. The duration between plasmid
injection and EP was 20 seconds. The sequence of events
for plasmid injection/EP was as follows: (1) the disposable
electrode assembly is placed in the receptacle of the handle,
and the initiation button on the handle is pressed; (2) IM
injection of 20 mL (5 mg/mL) of HIF-1a plasmid DNA is
administered using an insulin syringe with a 30-gauge
needle; (3) immediately, the three array needles are
placed into the area surrounding the injection site; (4) the
initiation button on handle is then pressed, and after a 4-
second countdown, pulse is delivered. The arrays are
then gently removed from the muscle. The same sequence
was repeated for the pVAX-EP group.
Limb perfusion measurement. Baseline limb perfu-
sion measurements were performed preoperatively using
laser Doppler perfusion imager (LDPI) and repeated
immediately postsurgical ligation of the femoral artery as
previously described.9 Brieﬂy, serial perfusion measure-
ments were performed at each time point using LDPI(Moor Instruments Inc, Wilmington, Del). The perfusion
ratio was calculated (ligated/nonligated limb) and averages
obtained for each mouse at each time point. The perfusion
signal was displayed in color codes ranging from dark blue
(0) through red to white (1000).
Foot movement and necrosis scores. To assess func-
tional recovery of hindlimb, a scoring system based on active
foot movement was done serially by a blinded observer
unaware of the treatment groups at each time point, using
touch as previously described.10 Brieﬂy, scoring was per-
formed as follows: score 0, no leg use; score 1, use of the leg;
score 2, active foot use; score 3, use of complete foot or
spreading of the toes; and score 4, unrestricted movement.
Additionally, the severity of necrosis was scored by a simi-
larly blinded observer to assess mice that require euthanasia
at each time point. Brieﬂy, scoring was performed as follows:
score 0, no necrosis; score 1, cyanosis/discoloration; score
2, necrosis/loss of one to two toes; score 3, necrosis/loss of
three to ﬁve toes; score 4, severe necrosis (extending to
dorsum pedis or higher). Mice scoring $3 or with limb
autoamputation were euthanized.
Tissue harvest and immunohistochemistry for
necrosis and angiogenesis. Tissue harvest and morpho-
metric analysis were performed on day 21 for necrosis anal-
ysis. Immunohistochemistry for capillary growth and
collateral vessel formation/remodeling were performed as
previously described.11,12 Brieﬂy, mice were sacriﬁced by
CO2 inhalation and perfused intracardially with phosphate-
buffered saline followed by 4% paraformaldehyde. The
adductor muscles were dissected, ﬁxed in 4% para-
formaldehyde for 48 hours, and embedded in parafﬁn before
sectioning using cryostat (section of 10-15 mm). For
morphometric analysis, sections were stained with hema-
toxylin and eosin and mounted on Fluoromount-G media
(SouthernBiotech,Birmingham,Ala) to evaluate for percent
tissue necrosis. Immunoﬂuorescent staining was performed
as described previously.13 Brieﬂy, staining for CD31 was
performed using mouse monoclonal antibody against
human CD31 (Dako Cytomation, Inc, Carpentaria, Calif)
and counterstained with Texas Red ﬂuorescent dye (Gene
Link Inc, Hawthorne, NY) to detect vascular endothelial
cells. Mouse monoclonal antibodies against a-SMA
(Research Diagnostics Inc, Flanders, NJ) was used and was
counterstained with Alexa 568 ﬂuorescent dye (Life Tech-
nologies, Grand Island, NY) to detect vascular smooth
muscle cells. Irradiation with microwave was performed for
antigen retrieval. Sections were incubated in 0.3% hydrogen
peroxide to block peroxidase activity. Protein blocking,
incubation with secondary biotinylated antibody, and
avatin-biotin interaction were performed using the Vectas-
tain kit (Vector Laboratories, Burlingame, Calif). Quantiﬁ-
cation for necrosis, capillary growth, and collateral vessel
formationwere done on an average of ﬁve randomly selected
ﬁelds at 200 magniﬁcation per tissue slide and analysis
performed using Image J software as previously described.12
Statistical analysis. Summary statistics are presented
as sample size and mean 6 standard error of mean. Calcu-
lated variables for analysis include LDPI ratios for each
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point. Concurrently, clinical foot movement, necrosis
score, and immunohistochemical analysis results were
assessed. The data follow a two-factor mixed-effects
experimental design with one repeated factor (day) and one
nonrepeated factor (treatment). Recognizing the presence
of effect modiﬁcation of treatment with advancing days
following surgery, simple effects of treatment on contin-
uous response variables was assessed by an analysis of
variance appropriate for a one-way ﬁxed-effect model
for each day. When statistically signiﬁcant differences
were found among treatment groups, differences between
pairwise comparisons of treatment groups were assessed
by application of Bonferonni adjustment for multiple
comparisons for each day. When assumptions for analysis of
variance appeared to be unreasonable, the Wilcoxon rank-
sum nonparametric test was performed. Contingency tables
of limb necrosis score vs treatment group were analyzed by
Pearson uncorrected c2 test to assess distribution of limb
necrosis score differences among the treatment groups. For
all tests of hypothesis, type I error (a) was ﬁxed at .05 for
declaring statistical signiﬁcance. All analyses were per-
formed using STATA (Intercooled), version 11 statistical
software (STATACorp, LP, College Station, Tex).
RESULTS
In vivo EP of HIF-1a DNA and limb blood ﬂow
recovery. LDPI measurements showed acutely reduced
ﬂow in the ligated limbs as compared with nonligated limbs
on day 0, consistent with successful femoral artery ligation
(Fig 2, A). Furthermore, serial LDPI measurements
revealed steady blood ﬂow recovery in the ligated limbs,
but at variable rates and consistency. Blood ﬂow recovery
was evident on days 3 through day 7 in the active treatment
group (HIF-EP) and in the positive control group (HIF-
IM). Paradoxically, recovery decreased in both groups on
day 14, but it increased on day 21. Overall, HIF-EP mice
had similar ﬂow recovery from day 3 to day 14 as compared
with HIF-IM mice. Signiﬁcant improvement in limb blood
ﬂow between HIF-EP and HIF-IM was detected on day
21 (1.03 6 0.15 vs 0.78 6 0.064; Fig 2, B). Expectedly,
blood ﬂow recovery was maintained at a much slower rate
in the pVAX-EP group.
Limb function recovery and in vivo EP of HIF-1a
DNA. As expected, there was acute limb functional
impairment on day 0 for all three treatment groups. Again,
HIF-EP and HIF-IM mice displayed similar improvement
in limb function spanning days 3 through 14. Statistically
signiﬁcant difference in foot movement score was only seen
on day 21 (3.56 0.58 vs 2.46 1.14; P < .05). The pVAX-
EP mice displayed the worst limb function recovery all
through day 21 (Fig 2, C).
In vivo EP of HIF-1a DNA and limb necrosis.
Limb functional recovery correlated with degree of necrosis
and/or need for euthanasia due to severe necrosis or auto-
amputation. HIF-EP mice showed the lowest rate of limb
necrosis (limb necrosis score <3) and auto-amputation
requiring euthanasia as compared with HIF-IM mice(77% 6 12% vs 43% 6 14%; P < .05) and HIF-EP
compared with pVAX-EP (77% 6 12% vs 17% 6 11%;
P < .01; Fig 2, D).
Tissue necrosis, capillary density, collateral vessels
and vascular area. Representative photomicrographs of
adductor muscles tissue sections stained on day 21 with
hematoxylin and eosin and immunoﬂuorescence dyes for
necrosis, CD31-positive endothelial cells, and a-SMA-
positive vessels are shown in Fig 3, A and C, respectively.
The HIF-EP mice had less adductor muscle necrosis
compared with the control mice at day 21 (HIF-EP vs
HIF-IM, 20.7% 6 1.75% vs 44% 6 3.73%; P < .001; HIF-
EP vs pVAX-EP, 20.7% 6 1.75% vs 60.05% 6 2.17%; P <
.0001; and HIF-IM vs pVAX-EP, 44% 6 3.73% vs
60.05% 6 2.17%; P < .01; Fig 3, B).
Capillary density (CD31þ endothelial cells) increased
in adductor muscles of HIF-EP mice compared with the
control groups (HIF-EP vs HIF-IM, 96.83 6 5.72
vessels/high-powered ﬁeld [hpf] vs 62.87 6 2.0 vessels/
hpf; P < .001; HIF-EP vs pVAX-EP, 96.83 6 5.72
vessels/hpf vs 39.37 6 2.76 vessels/hpf; P < .0001; and
HIF-IM vs pVAX/EP, 62.87 6 2.0 vessels/hpf vs
39.37 6 2.76 vessels/hpf; P < .001; Fig 3, D).
Collateral vessels number/vessel remodeling was also
increased in the HIF-EP mice compared with the control
groups (HIF-EP vs HIF-IM, 76.33 6 1.94 vessels/hpf vs
37.5 6 1.56 vessels/hpf; P < .0001; HIF-EP vs pVAX-
EP, 76.33 6 1.94 vessels/hpf vs 18.5 6 1.34 vessels/hpf;
P < .00001; and HIF-IM vs pVAX-EP, 37.5 6 1.56
vessels/hpf vs 18.56 1.34 vessels/hpf; P< .001; Fig 4,A).
Finally, total vessel area was larger in the HIF-EP
compared with the controls (HIF-EP vs HIF-IM,
15,521.67 6 1298.16 mm2 vs 7788.87 6 392.04 mm2;
P < .001; HIF-EP vs pVAX-EP, 15,521.67 6 1298.16
mm2 vs 4640.25 6 614.01 mm2; P < .0001; and HIF-
IM vs pVAX-EP, 7788.87 6 392.04 mm2 vs 4640.25 6
614.01 mm2; P < .05; Fig 4, B).DISCUSSION
In our study, we evaluated the utility of a simple, non-
invasive method of DNA transfer (in vivo EP) to deliver the
constitutively expressed HIF-1a plasmid DNA in a mouse
model of limb ischemia. The proangiogenic effects were
compared with the mice that received IM injection of
HIF-1a plasmid DNA alone. We observed statistically
signiﬁcant improvement in limb perfusion recovery, physi-
ological limb function, and improved vascularity at the
capillary level; vascular remodeling; and tissue morphologic
features on day 21 in mice treated with in vivo EP
compared with the controls. Furthermore, there was
a signiﬁcant statistical difference in the rate of limb necrosis
and auto-amputation between the two treatment groups.
Why were there signiﬁcant differences only seen at
endpoint day 21? We postulate that there was more sus-
tained expression of HIF-1a DNA in the in vivo EP-
treated group; the rates of DNA expression could be
similar in both modalities early in the course of time, but
Fig 2. A, Time course of hindlimb blood ﬂow after femoral artery ligation followed by either electroporation (EP) of
injected plasmid (hypoxia-inducible factor-EP [HIF-EP] and empty backbone plasmid DNA-EP [pVAX-EP]) or
injected plasmid alone (hypoxia-inducible factor-intramuscular injection [HIF-IM]). The representative laser Doppler
perfusion imager (LDPI) are recorded on the days indicated. Acute reduction in blood ﬂow was apparent in the left limb
(ligated, white arrows) as indicated in blue, on day 0 after femoral artery ligation. Sustained blood ﬂow recovery was
observed in the group treated with HIF-EP as compared with the other two groups (HIF-IM and pVAX-EP). The
perfusion signal is displayed in color codes. Poor perfusion is blue (0) and good perfusion ranges from red to white
(1000). B, Treatment with hypoxia-inducible factor 1 alpha (HIF-1a) DNA followed by EP improves limb perfusion
recovery postfemoral artery ligation in mice. Limb perfusion recovery was performed serially from the preoperative day
through postoperative day 21 using LDPI. Mean perfusion ratios (ligated/nonligated limb) were calculated for each
mouse at each time point and for each treatment group. The data are expressed as mean 6 standard error of the mean
(error bars across each animal) for statistical signiﬁcance through day 21 (P < .05). *HIF-EP vs pVAX-EP; P < .001;
**HIF-IM vs pVAX-EP; P < .01; and aHIF-EP vs HIF-IM; P < .05. C, Clinical foot movement was improved post-
femoral artery ligation in mice treated with HIF-1a DNA followed by EP. Foot movement was determined and scored
0 to 4 as a functional readout parameter to assess functional deﬁcit after ischemia induction. Active foot movement was
signiﬁcantly impaired in pVAX-EP mice but signiﬁcantly improved in the HIF-EP mice on day 21. The data are mean6
standard error of the mean (error bars across each mice) for statistical signiﬁcance (P < .05). *HIF-EP vs pVAX-EP; P<
.001; **HIF-IM vs pVAX-EP; P< .01; and aHIF-EP vs HIF-IM; P< .05.D,Clinical limb necrosis score was improved
over 21 days in mice treated with HIF-1a followed by EP. A clinical scoring system from 0 to 4 was used to determine
the rate of limb necrosis postfemoral artery ligation, and mice with scores $3 were deemed to have severe necrosis and
were euthanized. More pVAX-EP mice were likely to have limb necrosis >3 requiring euthanasia when compared with
HIF-EP and HIF-IM mice. Data are summarized as mean 6 standard error of the mean (error bars) for the 39 mice
through day 21, (HIF-EP, n ¼ 13; HIF-IM, n ¼ 14; pVAX-EP, n ¼ 12), statistical signiﬁcance at P < .05.
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and retention mediated by early differences in HIF-1a
expression, resulting in a sustained therapeutic effect peak-
ing on day 21. As will be further explained below, this
effect can be demonstrated by gene expression analysis.Presently, there are no effective noninvasive modalities
to deliver proangiogenic genes to promote clinically rele-
vant therapeutic angiogenesis in ischemic tissue. The
concept of EP entails the use of short high-voltage pulses
in order to overcome the cell membrane barrier. External
Fig 3. A, Representative photomicrographs (original magniﬁcation, 200) of adductor muscle tissue sections stained
with hematoxylin and eosin (H&E) on day 21 revealing that there were more necrotic tissue areas (dark blue) in the
ligated muscles in the negative control group (empty backbone plasmid DNA-electroporation [pVAX-EP]), compared
with the positive control group (hypoxia-inducible factor-intramuscular injection [HIF-IM]). There was less necrotic
inﬁltrating inﬂammatory cells in the active treatment group (HIF-EP). B, Summarized quantitative data revealed
signiﬁcantly fewer percent areas of necrotic tissues in the active treatment group (HIF-EP) as compared with the
positive control group (HIF-IM) and the negative control group (pVAX-EP). Data presented as mean 6 standard
error of the mean (error bars) at statistical signiﬁcance set at P < .05. *P < .001 (HIF-EP vs HIF-IM); **P < .01
(HIF-IM vs pVAX-EP); and #P < .0001 (HIF-EP vs pVAX-EP). C, Representative photomicrograph (original
magniﬁcation, 200) of adductor muscle tissue stained for CD31þ capillaries on day 21 to quantify capillary density.
The number of CD31þ capillaries (bright red) was more in the ligated limb muscles that received HIF-EP treatment
as compared with those that received negative control therapy (pVAX-EP) and positive control (HIF-IM). D,
Quantitative data summary demonstrated that CD31þ capillaries were signiﬁcantly higher in the active treatment
group (HIF-EP) compared with the negative control group (pVAX-EP) and the positive control group (HIF-IM).
Data presented as mean 6 standard error of the mean, statistical signiﬁcance at P < .05. *P < .001 (HIF-EP vs HIF-
IM); **P < .001 (HIF-IM vs pVAX-EP); and #P < .0001 (HIF-EP vs pVAX-EP).
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potential, thereby facilitating a transient reversible break-
down of the cell membrane. This results in a permeable
state of the cell membrane, and cells can be loaded with
a variety of molecules either through simple diffusion or
by electrophoresis, as in this case of DNA transfer.
In vivo EP of HIF-1a plasmid DNA in ischemic tissue
has been evaluated elsewhere, and that study demon-
strated effectiveness of this modality in promoting wound
healing and increased levels of HIF-1a gene expression in
old diabetic mce.14 In addition, the gene encoding ﬁbro-
blast growth factor, a proangiogenic growth factor, hasbeen delivered via in vivo EP and demonstrated efﬁcacy
in reversing limb ischemia in mice.15,16 Therefore, there
are clinical implications related to these ﬁndings that could
potentially be applied in gene delivery for therapeutic
angiogenesis.
Although several animal studies applying constitutively
expressed transcription factor HIF-1a have suggested efﬁ-
cacy in restoring limb perfusion,17,18 as well as cardio
protection,19 success has not been replicated in human
clinical trials. Furthermore, various delivery modalities
have been applied to the treatment of PAD and CLI in
clinical trials. For the most part, these modalities are
AB
Fig 4. A, Summarized quantitative data showed that smooth
muscle actin (SMA)þ vessels (vascular remodeling/collaterals)
were signiﬁcantly higher in the active treatment group (hypoxia-
inducible factor-electroporation [HIF-EP]) compared with the
negative control group (empty backbone plasmid DNA-EP
[pVAX-EP]) and the positive control group (hypoxia-inducible
factor-intramuscular injection [HIF-IM]). Data presented as
mean 6 standard error of the mean, statistical signiﬁcance at P <
.05. *P < .0001 (HIF-EP vs HIF-IM); **P < .0001 (HIF-IM vs
pVAX-EP); and #P < .001 (HIF-EP vs pVAX-EP). B,Quantitative
data summary demonstrated that the SMAþ vessels were signiﬁ-
cantly larger in total area (mm2) in the active treatment group
(HIF-EP) compared with the negative control group (pVAX-EP)
and the positive control group (HIF-IM). Statistical signiﬁcance
was set at P < .05. *P < .001 (HIF-EP vs HIF-IM); **P < .05
(HIF-IM vs pVAX-EP); and #P < .0001 (HIF-EP vs pVAX-EP).
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due to the following reasons: (1) angiogenesis is a complex
process that may require more than one growth factor or
stem cell to affect therapeutic response; (2) host barriers,
including the immune system, neutralize genes delivered
by viral vectors, and endogenous nucleases degrade naked
plasmid DNA and the potential incapability by the host to
integrate and express cloned genes; (3) imprecise and non-
standardized dosage of genes, growth factors, or stem cells;
(4) short half-life of most growth factors; and (5) inability
to deliver genes, growth factors, and cells to speciﬁc targetsites without adverse systemic effects.20 These barriers are
usually encountered through the use of viral-based vector
delivery methods, such as the use of lentivirus, adeno-
associated virus, or naked plasmid DNA, perhaps combined
with a carrier molecule. Unfortunately, the intramuscular
injection approach can be inefﬁcient in promoting uptake
of the plasmid by cells resulting in low levels of gene expres-
sion,21 and the intravascular methods are invasive and may
involve systemic effects beyond the targeted vascular bed.
Therefore, in this study,we showed that in vivoEP is a nonin-
vasive method that can potentially be used to selectively
deliver proangiogenic DNA in a targeted vascular bed to
promote limp perfusion recovery in a mouse model of CLI.
HIF-1a directly regulates the expression of the vascular
endothelial growth factor gene and other proangiogenic
genes, including placental growth factor, angiopoietin-2,
platelet-derived growth factor-2, and platelet-derived
growth factor-B.17,18,22 Therefore, the ability of HIF-1a
to regulate multiple proangiogenic growth factors down-
streammakes it a uniquegene tobe applied as amaster switch
for therapeutic angiogenesis. Some mechanisms of action of
proangiogenic growth factors in response to ischemia have
been postulated: (1) they act on endothelial cells and peri-
cytes within blood vessels surrounding the injured tissue to
induce angiogenesis; and (2) they function to recruit circu-
lating angiogenic cells into peripheral blood.14 On the other
hand, in vivo EP is thought to improve gene transfer efﬁ-
ciency to muscle cells, which results in increased expression
of the target gene.16 The application of in vivo EP has not
been used in PAD or CLI clinical studies; however, this
modality was shown to improve ischemic hindlimb blood
ﬂow and angiogenesis in animal models when combined
with ﬁbroblast growth factor.15,16 Indeed, in vivo EP has
been applied to augment the uptake and expression of naked
plasmid DNA in the dermis and other target tissues and was
associated with tissue-speciﬁc expression.23-25 Moreover,
this modality has been successfully applied in wound heal-
ing14,26 and vaccine therapies.27-29 Admittedly, local tissue
injury is expected with EP, even though we did not show
this in the current experiment; electrical stimulation in clin-
ical therapeutic angiogenesis may require use of anesthesia,
which should present no more risk than that experienced
in electroconvulsive therapy or cardioversion.
The limitations of this experiment include the fact that
gene expression analysis to quantify the efﬁcacy of gene
uptake and expression among the groups was not per-
formed. Future experiments will examine the mRNA
expression of HIF-1a DNA and its target proangiogenic
growth factors such as vascular endothelial growth factor-
A, angiopoietin-2, stromal cell-derived factor-1a, and endo-
thelial nitric oxide synthase at the speciﬁed time points.
Quantitative reverse polymerase chain reaction and
Northern blot will be performed and analyzed for linear
association between the mode of DNA transfection and
gene expression. The analysis would conﬁrm the range of
plasmid DNA uptake and expression in the adductor
muscles and show whether EP has a limited local effect or
allows for greater spread of the plasmid DNA to cover
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femoral artery ligation in a mouse model might not charac-
terize clinical atherosclerosis in its complexity as seen in
humans, and we plan to explore potential hindlimb ischemia
models that closely resemble clinical atherosclerosis.
Because this is a proof of principle experiment, we used
a single dose of HIF-1a plasmid DNA. Further studies will
seek to deﬁne a dose-response relationship to this delivery
modality, which will be important in determining if repeat
dosages are required, especially in a large animal model.
CONCLUSIONS
Our study demonstrated that in vivo EP of constitu-
tively expressed HIF-1a plasmid DNA improves perfusion
and reduces necrosis in a mouse model of hindlimb
ischemia. In vivo EP also improves survival from severe
limb necrosis and autoamputation, reduces tissue necrosis,
and increases the number of new capillaries and the forma-
tion of larger collateral vessels. Thus, the application of this
noninvasive, nonviral therapeutic modality of DNA
delivery may improve neovascularization, limb perfusion,
and salvage in CLI patients and warrants further studies.
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